Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Redox Hardcore
Ingredient used in the production of the supplement is contaminated with ethylene oxide. Potential consequences: poisoning, irritation, allergic reactions.
Thioealth
Control activities by the Voivodeship Pharmaceutical Inspector confirmed the presence of a piece of glass in one vial of the product, creating a direct risk to patients’ health or life during administration of the solution for injection. Potential effects: tissue damage, embolism, thromboembolic complications, life-threatening conditions.
Moja Figura – Appetite Suppression
The component used in production was contaminated with ethylene oxide, which poses a serious health risk to consumers. Potencjalne skutki: poisoning, gastrointestinal irritation, allergic reactions, general disturbances.
Aribit
An out-of-specification result was obtained in long-term stability testing for the parameter: aripiprazole active substance content, confirming that the product does not meet quality requirements. Potential effects: lack of treatment efficacy or adverse effects related to an incorrect dose.
Champix
the finding of N-nitroso-varenicline above the limits set by the COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP). Potential effects: possible long-term toxic effects, including an increased risk of cancer.
Champix
The presence of N-nitroso-varenicline in CHAMPIX was found at levels exceeding the limits set by the CHMP. Potential effects: possible carcinogenic action and other toxic effects.
Valzek
An exceedance of the limit for the impurity 5-(4'-(azidomethyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole was found in batches of the active substance used to manufacture the product. Potential effects: poisoning, toxic effects, serious adverse reactions.
Valzek
An exceeded limit was found for the impurity 5-(4'-(azidomethyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole in batches of the active substance used to manufacture Valzek (Valsartan) tablets. Potential effects: possible toxic effects of the impurity and a health risk to patients.
Lakea
Exceeding the limit of impurity 5-[4'-[(5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl]-[1,1'-biphenyl]-2-yl]-1H-tetrazole was found in the active substance used to manufacture the tablets. Potential effects: possible toxic effects and lack of full therapy safety.
Mitocin 20 mg
In batch no. 0-20022AB an out-of-specification result was found due to the presence of visible particles in the product intended for solution for injection. Potential effects: embolism, inflammation, inflammatory reactions, local or systemic complications.
Ciprofloxacin Kabi 400 mg/200 ml roztwór do infuzji
It was found that Ciprofloxacin Kabi cartons contained bottles labeled Glucosum 5% Fresenius with the same batch number, indicating mix-up of infusion products and risk of administering the wrong medicine. Potential effects: lack of efficacy, infusion-related complications.
Arpixor
According to the MAH’s representative, there is a justified suspicion that the Arpixor 30 mg, 56 tablets batch does not meet quality requirements regarding appearance. Potential effects: lack of treatment effectiveness or unpredictable drug action.
Arpixor
The abnormal appearance of the tablets does not meet the product’s quality requirements and may lead to interruption of pharmacotherapy, which in turn may pose a risk to patients’ life or health. Potential effects: worsening of the disease, complications, risk to life or health.
Bisoratio ASA
Out-of-specification results were found for the parameter of related substances and total bisoprolol impurities during long-term 12‑month stability studies, which may affect the safety and efficacy of the medicine. Potential effects: reduced treatment effectiveness, adverse reactions, cardiovascular complications.
Apo-Simva 40
A confirmed out-of-specification result was found for cross-contamination of the medicinal product with acetylsalicylic acid and salicylic acid. Potential effects: risk of adverse effects, allergic reactions, bleeding or other complications due to unintended intake of additional active substances.
Ozzion
An out-of-specification result was found for the release parameter, meaning the drug may not release the active substance correctly and may not ensure effective therapy. Potential effects: lack of treatment efficacy, worsening of symptoms, complications.
Champix
The presence of N-nitroso-varenicline contamination was found in the bulk product batch, with the level of this impurity exceeding the limit set based on ICH M7 guidance. Potential effects: possible carcinogenic effect and other serious adverse reactions.
Amiodaron Hameln
Particles were detected in some ampoules of the concentrate for solution for injection or infusion, which according to the specification should be clear, light yellow and free from visible particles. Potential effects: risk of emboli, local reactions, circulatory complications or other serious complications during intravenous administration.
Flutixon Neb
An out-of-specification result was found for the content of related substances in the product batches, which constitutes a quality defect and a potential risk to patients' health. Potential effects: possible adverse reactions, altered treatment efficacy, unpredictable bodily responses.
Flutixon Neb
An out-of-specification result was found regarding the content of related substances in the medicinal product Flutixon Neb. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.